| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acquired elliptocytosis as presenting sign of a myelodysplastic syndrome associated with deletion of chromosome 20 and mutations in TET2, DNMT3A, and U2AF1
|
Robier, Christoph
|
|
|
100 |
8 |
p. 2111-2112
|
artikel
|
| 2 |
A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT
|
Schäfer, Henning
|
|
|
100 |
8 |
p. 2095-2103
|
artikel
|
| 3 |
Association of KLOTHO polymorphisms with clinical complications of sickle cell anemia
|
Batista, Jéssica V. G. F.
|
|
|
100 |
8 |
p. 1921-1927
|
artikel
|
| 4 |
Blood and platelet transfusion from a donor with presymptomatic Covid-19
|
Liapis, Konstantinos
|
|
|
100 |
8 |
p. 2133-2134
|
artikel
|
| 5 |
Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial
|
Lee, Ji Hyun
|
|
|
100 |
8 |
p. 2051-2059
|
artikel
|
| 6 |
Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients
|
Janusz, Kamila
|
|
|
100 |
8 |
p. 1995-2004
|
artikel
|
| 7 |
Correction to: Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group
|
Schuler, Esther
|
|
|
100 |
8 |
p. 2141-2142
|
artikel
|
| 8 |
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K
|
Mian, Afsar Ali
|
|
|
100 |
8 |
p. 2023-2029
|
artikel
|
| 9 |
Diagnosis and management of non-clonal erythrocytosis remains challenging: a single centre clinical experience
|
Anžej Doma, Saša
|
|
|
100 |
8 |
p. 1965-1973
|
artikel
|
| 10 |
Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms
|
Huenerbein, Karlo
|
|
|
100 |
8 |
p. 2015-2022
|
artikel
|
| 11 |
Eculizumab, a real-life successful treatment for refractory cold agglutinin–mediated auto-immune hemolytic anemia secondary to lymphoproliferative disorders
|
Herbreteau, Laura
|
|
|
100 |
8 |
p. 2105-2106
|
artikel
|
| 12 |
Elevated plasma hemoglobin in COVID-19–related illnesses: a critical appraisal
|
Tiwari, Nishant R.
|
|
|
100 |
8 |
p. 2125-2126
|
artikel
|
| 13 |
Extracellular vesicles from thalassemia patients carry iron-containing ferritin and hemichrome that promote cardiac cell proliferation
|
Atipimonpat, Anyapat
|
|
|
100 |
8 |
p. 1929-1946
|
artikel
|
| 14 |
Faggot cells in acute myeloid leukemia with t(7;11)(p15;p15) and NUP98-HOXA9 fusion
|
Yanagisawa, Hiroto
|
|
|
100 |
8 |
p. 2121-2123
|
artikel
|
| 15 |
Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome—excess blasts detected by next-generation sequencing technique
|
Owattanapanich, Weerapat
|
|
|
100 |
8 |
p. 1983-1993
|
artikel
|
| 16 |
Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort
|
Virk, Harpreet
|
|
|
100 |
8 |
p. 2031-2041
|
artikel
|
| 17 |
δ-Hemoglobinopathies in Thailand: screening, molecular basis, genotype-phenotype interaction, and implication for prevention and control of thalassemia
|
Singha, Kritsada
|
|
|
100 |
8 |
p. 1953-1963
|
artikel
|
| 18 |
Hemolytic erythrocytosis: an amalgamated phenotype from coinherited Chuvash polycythemia and G6PD Kerala-Kalyan with acquired transient stomatocytosis
|
Jamwal, Manu
|
|
|
100 |
8 |
p. 2107-2109
|
artikel
|
| 19 |
Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data
|
Derigs, Patrick
|
|
|
100 |
8 |
p. 2087-2093
|
artikel
|
| 20 |
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib
|
Caocci, Giovanni
|
|
|
100 |
8 |
p. 2005-2014
|
artikel
|
| 21 |
Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients—a single-center retrospective study
|
Regidor, Bernard
|
|
|
100 |
8 |
p. 2061-2070
|
artikel
|
| 22 |
Management of chronic patients during the COVID-19 pandemic: the experience of a referral center for rare hematological disorders in the hardest-hit region in Italy
|
Motta, Irene
|
|
|
100 |
8 |
p. 2129-2131
|
artikel
|
| 23 |
Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab
|
Di Prima, Alessio
|
|
|
100 |
8 |
p. 2117-2119
|
artikel
|
| 24 |
Oral mucositis in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation in relation to the conditioning used prior to transplantation
|
Wysocka-Słowik, Aleksandra
|
|
|
100 |
8 |
p. 2079-2086
|
artikel
|
| 25 |
Paroxysmal nocturnal hemoglobinuria complicated with essential thrombocythemia harboring concomitant PIGA, CALR, and ASXL1 mutations
|
Okamoto, Haruya
|
|
|
100 |
8 |
p. 2113-2115
|
artikel
|
| 26 |
Plasma hemoglobin in COVID-19: authors’ reply
|
Lancman, Guido
|
|
|
100 |
8 |
p. 2127
|
artikel
|
| 27 |
Pre-transplant donor-type red cell transfusion is a safe and effective strategy to reduce isohemagglutinin titers and prevent donor marrow infusion reactions in major ABO-mismatched transplants
|
Mehta, Pallavi
|
|
|
100 |
8 |
p. 2071-2078
|
artikel
|
| 28 |
Priapism in patients with hemolytic disorders: a nationwide retrospective cohort study
|
Tranekær, Stinne
|
|
|
100 |
8 |
p. 1947-1951
|
artikel
|
| 29 |
Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry
|
Zimmermann, Heiner
|
|
|
100 |
8 |
p. 2043-2050
|
artikel
|
| 30 |
Severe exacerbation of immune thrombocytopenia and COVID-19: the favorable response to corticosteroid-based therapy—a case report
|
Hu, Zhiliang
|
|
|
100 |
8 |
p. 2135-2137
|
artikel
|
| 31 |
The clinical significance of PNH-phenotype cells accounting for < 0.01% of total granulocytes detected by the Clinical and Laboratory Standards Institute methods in patients with bone marrow failure
|
Hosokawa, Kohei
|
|
|
100 |
8 |
p. 1975-1982
|
artikel
|
| 32 |
Thrombocytopenia in COVID-19: pathophysiology matters
|
Gavriilaki, Eleni
|
|
|
100 |
8 |
p. 2139-2140
|
artikel
|
Tijdschrift beschrijving